Posts by Peter W. PENG

From October 19th to 20th, 2024, the inaugural St.Gallen International Breast Cancer Conference (SGBCC) China Tour was successfully held in Nanjing. The St.Gallen International Breast Cancer Conference is the most influential international conference globally concerning the diagnosis and treatment of early-stage breast cancer. Professor Michael Gnant, the chairman of the St.Gallen Breast Cancer Consensus Meeting,

The final results of the KEYNOTE-522 trial confirm the potential of pembrolizumab to change patient management, though careful patient selection and toxicity monitoring are essential.

Microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC) has shown minimal response to immune checkpoint inhibitors as monotherapy, making combination immunotherapy a key strategy to address this clinical challenge. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), a multicenter phase II study led by Dr. Rongbo Lin from Fujian Cancer Hospital was selected for the poster abstract session (Abstract #198). This study evaluates the preliminary efficacy and safety of FOLFOXIRI combined with bevacizumab and cadonilimab in pMMR/MSS mCRC patients.  During the conference, a reporter from Oncology Frontier conducted an in-depth interview with Dr. Rongbo Lin to discuss the study findings.

Breast cancer has become one of the most common malignancies among women, with triple-negative breast cancer (TNBC) being considered the most aggressive subtype due to its historically poor prognosis. Looking back at 2024, significant research breakthroughs have emerged in both early-stage and advanced TNBC treatment, covering chemotherapy, targeted therapy, immunotherapy, and antibody-drug conjugates (ADCs). Many of these studies have been led by Chinese researchers, contributing to original findings in the field. In this annual review, Dr. Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University shares the key advancements in systemic therapy for TNBC, showcasing how precision medicine is gradually transforming TNBC treatment and offering patients a brighter future.

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was successfully held in Barcelona, Spain. At this conference, a study led by Dr. Guodong He from Zhongshan Hospital, utilizing…

Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by accelerated platelet destruction and impaired platelet production due to antibody-mediated mechanisms. Current first-line therapies for ITP include glucocorticoids and immunoglobulins, while second-line options often involve thrombopoietin receptor agonists (TPO-RAs), CD20 monoclonal antibodies, and splenectomy. The introduction of CD20 monoclonal antibody therapy over the past decade has transformed ITP treatment. However, heterogeneity in treatment response and duration leaves a subset of patients at risk of severe bleeding, reduced quality of life, and increased mortality. Following the success of CD20 antibodies, researchers have been exploring other potent therapeutic targets to address these unmet needs.

Editor’s Note: At the 2024 European Society for Medical Oncology (ESMO) Asia Annual Meeting, nine TiP abstracts focused on colorectal cancer from China were presented. Previously, we summarized four of…